Reinhart Charles A. III
Known title: Chief Financial OfficerCIK: 0001470871
Associated companies
Transaction History
| PCRX | ▲ Buy | Grant | 12,220 | $0 | 6/12/2024 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 2,979 | $92K | 6/3/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 9,000 | $0 | 6/14/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,371 | $52K | 6/7/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,236 | $48K | 6/6/2023 | View on chart |
| PCRX | ▲ Buy | Grant | 7,950 | $0 | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,516 | $154K | 6/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.